SIETES :: 92833 citas

Resultados de la búsqueda por FINANCIACIÓN REFINAR BÚSQUEDA

1.

Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D spending on single-enantiomer drugs versus their racemic precursors . Ann Intern Med 2019:13 de agosto. [Ref.ID 103162]

2.

Rejón R. La chequera de las farmacéuticas para médicos y congresos: 1.130 millones de euros en cuatro años . eldiario.es 2019:9 de julio. [Ref.ID 103157]

3.

4.

Sultana J, Moretti U, Addis A, Caduff P, Capuano A, Kant A, Laporte JR, Lindquist M, Raine J, Sartori D, Trifirò G, Tuccori M, Venegoni M, van Puijenbroek E, Leone R. Workshop on the Italian pharmacovigilance system in the international context: critical issues and perspectives. Drug Saf 2019;42:mayo. [Ref.ID 103115]

5.

Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, Groeneveld PW. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016. JAMA Intern Med 2018;178:julio. [Ref.ID 102882]

6.

Anónimo. Muscle drug determined too expensive for UK’s NHS. DIA Daily 2018:14 de agosto. [Ref.ID 102787]

7.

Mole B. “Is curing patients a sustainable business model?” Goldman Sachs analysts ask. Ars Technica 2018:12 de abril. [Ref.ID 102511]

8.

Anónimo. Senate investigation reveals five manufacturers funded groups that acted as opioid “cheerleaders.”. DIA Daily 2018:12. [Ref.ID 102455]

9.

Hamel MB. Speed, safety, and industry funding — From PDUFA I to PDUFA VI. N Engl J Med 2017;377:2278-86. [Ref.ID 102166]

10.

Godlee F, Abbasi K, Bloom T. BMJ declares its revenues from industry. BMJ 2017;359:j4930. [Ref.ID 102109]

11.

Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P. Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study. BMJ 2017;359:j4619. [Ref.ID 102108]

12.

Anónimo. Insys Therapeutics faked cancer diagnoses to sell more of its opioid medication, senator says. DIA Daily 2017:11. [Ref.ID 102048]

13.

Anónimo. NICE considers eliminating Sanofi, Ipsen thyroid cancer drugs From Cancer Drug Fund. DIA Daily 2017:2. [Ref.ID 102033]

14.

Iacobucci G. NHS to stop funding homeopathy and some drugs in targeted savings drive. BMJ 2017;358:j3560. [Ref.ID 102013]

15.

Anónimo. WHO’s travel expenses exceed what it spends on some diseases. DIA Daily 2017:1. [Ref.ID 101587]

16.

Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]

17.

Anónimo. Former investors sue Valeant for failing to successfully market flibanserin. DIA Daily 2016:4. [Ref.ID 101011]

18.

Anónimo. UK appeals court rules NHS has authority to fund PrEP medication for HIV. DIA Daily 2016:1. [Ref.ID 100918]

19.

Anónimo. Infliximab biosimilar dubbed noninferior in independent clinical trial by Norwegian government. DIA Daily 2016:6. [Ref.ID 100841]

20.

Anónimo. NICE rejects Bristol-Myers’ Opdivo as general first-line NSCLC treatment. DIA Daily 2016:2. [Ref.ID 100810]